Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately…
CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV) Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for…
Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023 Ferring Pharmaceuticals…
Lilly’s Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation Eli Lilly and Company (NYSE: LLY) has allocated an additional $50 million to its now $300 million Social Impact…
Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis Eli Lilly and Company (NYSE: LLY)…
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with…
152 million babies born preterm in the last decade An estimated 13.4 million babies were born pre-term in 2020, with nearly 1 million dying from preterm complications, according to a…
Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic The WHO Director-General has the pleasure of transmitting the Report of the fifteenth meeting of…
UAE and WHO deliver air lift of critical medical supplies to Sudan The United Arab Emirates (UAE) and the World Health Organization have delivered 30 tons of urgent medical supplies…
Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD) Ultomiris (ravulizumab) has been approved in the European Union (EU) as the first and only long-acting C5 complement…
Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to…
Koselugo approved in China for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas The approval by the National Medical Products Administration (NMPA) in China was based on positive results…